Top Page
PainChek Ltd
(Sydney:PCK)
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
PainChek Ltd Business Overview & Revenue Model
PainChek Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.51M | 3.36M | 2.67M | 1.95M | 978.57K | 214.80K |
| Gross Profit | 763.81K | 997.74K | 726.66K | 712.51K | -258.82K | -424.21K |
| EBITDA | -5.40M | -7.65M | -9.49M | -8.61M | -6.80M | -7.06M |
| Net Income | -5.42M | -7.67M | -8.31M | -7.57M | -5.72M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 2.15M | 4.18M | 2.80M | 6.65M | 11.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.62M | 1.62M | 3.56M | 2.51M | 6.14M | 11.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.26M | 3.26M | 2.89M | 2.13M | 1.83M | 3.57M |
| Stockholders Equity | -1.11M | -1.11M | 1.29M | 668.13K | 4.82M | 8.24M |
Cash Flow | ||||||
| Free Cash Flow | -5.71M | -6.77M | -7.16M | -6.34M | -7.02M | -4.18M |
| Operating Cash Flow | -5.70M | -6.75M | -7.13M | -6.32M | -7.00M | -4.12M |
| Investing Cash Flow | -12.17K | -12.17K | -34.25K | -12.44K | -21.96K | -60.03K |
| Financing Cash Flow | 4.82M | 4.82M | 8.21M | 2.70M | 1.75M | 9.48M |
PainChek Ltd Technical Analysis
PainChek Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$188.01M | 116.67 | 1.89% | ― | 10.06% | ― | |
54 Neutral | AU$140.98M | -23.26 | -12.35% | ― | 15.99% | 22.05% | |
52 Neutral | AU$21.37M | -11.84 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$58.12M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
42 Neutral | AU$55.39M | -6.06 | -8647.54% | ― | 25.98% | 22.10% |
PainChek Ltd Corporate Events
PainChek Limited has disclosed a change in the interests of director John Murray, who has allowed 40,000 options held indirectly through Nanjop Pty Ltd as trustee for the Murring Family Trust to lapse, resulting in no remaining options and no change to his total shareholding in the company. Following the lapse, Murray continues to hold 1,463,860 fully paid ordinary shares indirectly and 390,600 fully paid ordinary shares directly, a development that slightly alters the structure of his equity exposure by removing option-based incentives but leaves his direct and indirect share ownership unchanged, with no on-market trades reported and no closed-period trading issues raised.
PainChek Ltd has announced the expiry and cessation of 15,686,749 listed options (ASX code PCKAY) that carried an exercise price of A$0.50 and were due to expire on 19 December 2025, with the options lapsing unexercised. The expiry slightly simplifies the company’s capital structure by removing a large block of out-of-the-money options from its issued securities, which may clarify the potential future dilution profile for existing shareholders but does not immediately affect PainChek’s current cash position or operations.
PainChek Ltd has applied to the ASX for quotation of 24,775 new fully paid ordinary shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 23 December 2025. The relatively small share issuance modestly increases the company’s quoted capital base and reflects ongoing conversion of incentive or financing-related instruments, with limited immediate impact on its overall capital structure but indicating continued engagement from holders of convertible securities.
PainChek Ltd has issued 176,471 fully paid ordinary shares to directors under a previously announced placement to sophisticated, professional and other exempt investors, following shareholder approval at its 2025 Annual General Meeting. The company has confirmed that the shares were issued without a prospectus under the Corporations Act exemption, that it is up to date with its financial reporting and continuous disclosure obligations, and that there is no undisclosed price-sensitive information, providing assurance to the market and existing shareholders about regulatory compliance and transparency around the capital raising.
PainChek Limited has disclosed a change in the holdings of its managing director, Philip Daffas, who has increased his direct stake in the company through the issue of 147,059 fully paid ordinary shares, taking his total shareholding to 3,114,226 shares alongside existing options and performance rights. The new shares were issued as part of a placement previously approved by shareholders at the 2025 Annual General Meeting, signalling continued alignment between executive leadership and shareholders’ interests and underscoring board-level participation in the company’s capital-raising activities.
PainChek Ltd has applied to the ASX for quotation of 176,471 new fully paid ordinary shares, issued on 22 December 2025 under a previously announced transaction. The modest share issuance expands the company’s quoted capital base and reflects ongoing use of equity to support its corporate or transactional activities, with limited immediate dilution but signalling continued capital management as PainChek advances its digital health technology in the market.
PainChek Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 339 ordinary fully paid securities to be issued. This move is part of the company’s strategy to enhance its financial position and potentially expand its market presence, impacting its operations and offering potential benefits to stakeholders.
PainChek Ltd announced that all resolutions at its Annual General Meeting were passed, marking a significant step in its operational progress. The company’s AI-driven pain assessment tool continues to gain traction, with regulatory clearance across multiple countries and partnerships with numerous aged care facilities, enhancing its industry positioning and stakeholder engagement.
PainChek Ltd has announced the issuance of 276,747 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and potentially increase its shareholder base, reflecting its ongoing efforts to expand its operations and strengthen its position in the healthcare technology sector.
PainChek Ltd has announced that its shareholders will be able to view the Annual General Meeting presentations and listen to the meeting live online. This development highlights the company’s commitment to transparency and shareholder engagement. PainChek’s technology, which is already widely used in aged care facilities, is expanding into home care, signaling a strategic move to broaden its market reach and enhance its industry positioning.
PainChek Ltd has announced the quotation of 218,495 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from November 5, 2025. This move reflects the company’s ongoing efforts to strengthen its market presence and provide liquidity to its shareholders, potentially impacting its financial position and stakeholder value positively.
PainChek Ltd has received FDA De Novo clearance for its pain assessment device, granting it access to a $175 million AUD annual market in the US long-term care sector. The clearance positions PainChek for significant growth and expansion opportunities, including a potential $582 million AUD market through further regulatory pathways. The company has signed its first US commercial agreement and is actively building a sales pipeline, while also experiencing growth in its core markets and launching its Infant App in Australia.
PainChek Ltd announced an upcoming investor webinar to discuss their quarterly update and Appendix 4C, highlighting the company’s ongoing efforts to engage with stakeholders and provide transparency about their operations. The announcement underscores PainChek’s commitment to maintaining its position as a leader in pain assessment technology, with implications for expanding their market presence and enhancing stakeholder relations.
PainChek Limited announced a change in the director’s interest, with Philip Daffas converting 2,360,718 performance rights into fully paid ordinary shares and allowing 4,804,177 performance rights to lapse. This change reflects a strategic adjustment in the director’s holdings, potentially impacting the company’s stock dynamics and signaling confidence in the company’s future prospects.
PainChek Ltd has announced a security consolidation, affecting various securities including ordinary shares and options with different expiration dates and exercise prices. This reorganization is set to commence trading on a deferred settlement basis from November 28, 2025, with the record date on December 1, 2025, and the issue date on December 8, 2025. The consolidation may impact the company’s market operations and investor relations by potentially streamlining its security structure.
PainChek Ltd has announced the quotation of 5,601,300 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from October 22, 2025. This move is part of the company’s strategy to enhance its market presence and provide more liquidity to its shareholders, potentially impacting its financial standing and stakeholder confidence positively.
PainChek Ltd has announced the details of its upcoming Annual General Meeting, which will take place on November 26, 2025, in Sydney, Australia. The meeting will provide shareholders with the opportunity to view presentations and listen to discussions, although questions must be submitted in advance. This meeting is crucial for shareholders to engage with the company’s board and auditors regarding the company’s performance and strategy.
PainChek Ltd has announced the quotation of 9,444,665 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 16, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially support further growth initiatives. The issuance of these securities may impact the company’s market positioning by increasing its capital base, which could be beneficial for stakeholders looking for long-term value.
PainChek Ltd has appointed Sasha Grant as Head of Growth for its PainChek Infant App, aiming to scale up and roll out the app more effectively. Grant, known for her success with WikiCamps, is expected to enhance the app’s market presence and user experience. The PainChek Infant App, a unique AI-powered pain assessment tool for infants, has a potential market value of A$15 billion annually. Recent developments include technical updates, consumer feedback integration, and marketing strategy refinements, with expectations for increased downloads and revenue through improved registration processes and partnerships.
PainChek Limited has been granted a De Novo classification by the U.S. FDA for its PainChek Adult App, which has been formally recognized as a medical device for pain assessment with a new product code ‘SGB’. This significant regulatory milestone is expected to have a material effect on the company’s securities and enhances its market positioning as a leader in pain assessment technology.